|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Gomaa AI, Khan SA, Toledano MB, Waked I
and Taylor-Robinson SD: Hepatocellular carcinoma: Epidemiology,
risk factors and pathogenesis. World J Gastroenterol. 14:4300–4308.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang S, Yue M, Shu R, Cheng H and Hu P:
Recent advances in the management of hepatocellular carcinoma. J
BUON. 21:307–311. 2016.PubMed/NCBI
|
|
5
|
Ling CQ, Liu Q, Li DT, Yue XQ, Hou FG, Zhu
DZ, Yu CQ, Chen Z, Zhai XF and Yu Y: Study of a qualitative
diagnostic criterion for basic syndromes of traditional Chinese
medicine in patients with primary liver cancer. Zhong Xi Yi Jie He
Xue Bao. 3:95–98. 2005.(In Chinese). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wu P, Liu T and Hu Y: PI3K inhibitors for
cancer therapy: What has been achieved so far? Curr Med Chem.
16:916–930. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mabuchi S, Kuroda H, Takahashi R and
Sasano T: The PI3K/AKT/mTOR pathway as a therapeutic target in
ovarian cancer. Gynecol Oncol. 137:173–179. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yu HY, Kim SO, Jin CY, Kim GY, Kim WJ, Yoo
YH and Choi YH: β-lapachone-induced apoptosis of human gastric
carcinoma AGS cells is caspase-dependent and regulated by the
PI3K/Akt pathway. Biomol Ther (Seoul). 22:184–192. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fu YL, Zhang QH, Wang XW and He H:
Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell
growth by triggering G2/M cell cycle arrest and inhibition of
m-TOR/PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci.
21:1169–1175. 2017.PubMed/NCBI
|
|
10
|
Engelman JA: Targeting PI3K signalling in
cancer: Opportunities, challenges and limitations. Nat Rev Cancer.
9:550–562. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Geng R and Li J: Apatinib for the
treatment of gastric cancer. Expert Opin Pharmacother. 16:117–122.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Roviello G, Ravelli A, Polom K, Petrioli
R, Marano L, Marrelli D, Roviello F and Generali D: Apatinib: A
novel receptor tyrosine kinase inhibitor for the treatment of
gastric cancer. Cancer Lett. 372:187–191. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang H: Apatinib for molecular targeted
therapy in tumor. Drug Des Devel Ther. 9:6075–6081. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mi YJ, Liang YJ, Huang HB, Zhao HY, Wu CP,
Wang F, Tao LY, Zhang CZ, Dai CL, Tiwari AK, et al: Apatinib
(YN968D1) reverses multidrug resistance by inhibiting the efflux
function of multiple ATP-binding cassette transporters. Cancer Res.
70:7981–7991. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tian S, Quan H, Xie C, Guo H, Lü F, Xu Y,
Li J and Lou L: YN968D1 is a novel and selective inhibitor of
vascular endothelial growth factor receptor-2 tyrosine kinase with
potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
El-Serag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Frau M, Biasi F, Feo F and Pascale RM:
Prognostic markers and putative therapeutic targets for
hepatocellular carcinoma. Mol Aspects Med. 31:179–193. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li J, Qin S, Xu J, Guo W, Xiong J, Bai Y,
Sun G, Yang Y, Wang L, Xu N, et al: Apatinib for
chemotherapy-refractory advanced metastatic gastric cancer: Results
from a randomized, placebo-controlled, parallel-arm, phase II
trial. J Clin Oncol. 31:3219–3225. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fan M, Zhang J, Wang Z, Wang B, Zhang Q,
Zheng C, Li T, Ni C, Wu Z, Shao Z, et al: Phosphorylated VEGFR2 and
hypertension: Potential biomarkers to indicate VEGF-dependency of
advanced breast cancer in anti-angiogenic therapy. Breast Cancer
Res Treat. 143:141–151. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ohtsu A, Shah MA, Van Cutsem E, Rha SY,
Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, et al:
Bevacizumab in combination with chemotherapy as first-line therapy
in advanced gastric cancer: A randomized, double-blind,
placebo-controlled phase III study. J Clin Oncol. 29:3968–3976.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia M, Tong JH, Ji NN, Duan ML, Tan YH and
Xu JG: Tramadol regulates proliferation, migration and invasion via
PTEN/PI3K/AKT signaling in lung adenocarcinoma cells. Eur Rev Med
Pharmacol Sci. 20:2573–2580. 2016.PubMed/NCBI
|
|
22
|
Carnero A, Blanco-Aparicio C, Renner O,
Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer,
therapeutic implications. Curr Cancer Drug Targets. 8:187–198.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gondi CS, Kandhukuri N, Dinh DH, Gujrati M
and Rao JS: Down-regulation of uPAR and uPA activates
caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J
Oncol. 31:19–27. 2007.PubMed/NCBI
|
|
24
|
Roberts LR and Gores GJ: Hepatocellular
carcinoma: Molecular pathways and new therapeutic targets. Semin
Liver Dis. 25:212–225. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao JG, Zhang L, Xiang XJ, Yu F, Yu F, Ye
WL, Wu DP, Wang JF and Xiong JP: Erratum: Amarogentin secoiridoid
inhibits in vivo cancer cell growth in xenograft mice model and
induces apoptosis in human gastric cancer cells (SNU-16) through
G2/M cell cycle arrest and PI3K/Akt signalling pathway. J BUON.
21:13322016.PubMed/NCBI
|
|
26
|
Packham G and Cleveland JL: c-Myc and
apoptosis. Biochim Biophys Acta. 1242:11–28. 1995.PubMed/NCBI
|
|
27
|
Brady HJ and Gil-Gómez G: Bax. The
pro-apoptotic Bcl-2 family member, Bax. Int J Biochem Cell Biol.
30:647–650. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schroeder CP, Kadara H, Lotan D, Woo JK,
Lee HY, Hong WK and Lotan R: Involvement of mitochondrial and Akt
signaling pathways in augmented apoptosis induced by a combination
of low doses of celecoxib and N-(4-hydroxyphenyl) retinamide in
premalignant human bronchial epithelial cells. Cancer Res.
66:9762–9770. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agarwal S, Achari C, Praveen D, Roy KR,
Reddy GV and Reddanna P: Inhibition of 12-LOX and COX-2 reduces the
proliferation of human epidermoid carcinoma cells (A431) by
modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol.
18:939–946. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yin L, Wang J, Huang FC, Zhang YF, Xu N,
Wen ZQ, Li WL and Dong J: Inhibitory effect of apatinib on HCT-116
cells and its mechanism. Nan Fang Yi Ke Da Xue Xue Bao. 37:367–372.
2017.(In Chinese). PubMed/NCBI
|
